CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Trandolapril

群多普利 杂质对照品Trandolapril Impurities

EP23 个杂质条目23 impurity entries

本页汇总 群多普利 的 23 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 23 impurity reference standards of Trandolapril with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 群多普利(Trandolapril)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesStability-indicating HPLC determination of trandolapril in bulk drug and pharmaceutical dosage forms
    International journal of analytical chemistry · 2015 · Al-Hawash LA et al.  ·  PMID 25802524  ·  DOI
  2. 杂质研究Impurity studiesImpurity profiling of trandolapril under stress testing: Structure elucidation of by-products and development of degradation pathway
    International journal of pharmaceutics · 2012 · Dendeni M et al.  ·  PMID 22960502  ·  DOI
  3. 杂质研究Impurity studiesMELANOMA AND DYSPLASTIC NEVI DEVELOPMENT AFTER RANITIDINE/RILMENIDINE/МOXONIDINE, LERCANIDIPINE, ROSUVASTATIN AND VERAPAMIL/TRANDOLAPRIL - NEW DATA/CASE SERIES. THE POTENTIAL ROLE OF NITROSAMINE/NDSRIS CONTAMINATION IN POLYMEDICATION AS SUBSTANTIAL SKIN CANCER TRIGGERING FACTOR
    Georgian medical news · 2023 · Tchernev G, Naydekova N  ·  PMID 38236117
  4. 分析方法Analytical MethodsHptlc method development and validation of trandolapril in bulk and pharmaceutical dosage forms
    Journal of advanced pharmaceutical technology & research · 2010 · Sreekanth N et al.  ·  PMID 22247843
  5. 分析方法Analytical MethodsComparative pharmacokinetics of trandolapril, its active metabolite, and verapamil in human plasma of Egyptian population using HPLC-MS/MS
    Drug testing and analysis · 2018 · Magdy R et al.  ·  PMID 29319234  ·  DOI

群多普利 —— 原料药与杂质对照品Trandolapril — drug substance & impurities

共 24 个条目(含原料药本体)24 items incl. the drug substance
Trandolapril structure
EP原料药 APIAPI
群多普利Trandolapril
Trandolapril
CAS No.87679-37-6
Chemical FormulaC24H34N2O5
Purity>95%询价On request
10mg25mg50mg100mg
Trandolapril Impurity 1(Trandolapril EP Impurity A) structure
EPA
群多普利杂质1(群多普利EP杂质A)Trandolapril Impurity 1(Trandolapril EP Impurity A)
Trandolapril Impurity 1(Trandolapril EP Impurity A)
CAS No.118194-41-5
Chemical FormulaC23H32N2O5
Purity>95%询价On request
10mg25mg50mg100mg
Trandolapril Impurity 4(Trandolapril EP Impurity D) structure
EPD
群多普利杂质4(群多普利EP杂质D)Trandolapril Impurity 4(Trandolapril EP Impurity D)
Trandolapril Impurity 4(Trandolapril EP Impurity D)
CAS No.149881-40-3
Chemical FormulaC24H32N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Trandolapril Impurity 5(Trandolapril EP Impurity E) structure
EPE
群多普利杂质5(群多普利EP杂质E)Trandolapril Impurity 5(Trandolapril EP Impurity E)
Trandolapril Impurity 5(Trandolapril EP Impurity E)
CAS No.87679-71-8
Chemical FormulaC22H30N2O5
Purity>95%询价On request
10mg25mg50mg100mg
Trandolapril Impurity 5-d5(Trandolapril EP Impurity E-d5) structure
EPE-D5
群多普利杂质5-d5(群多普利EP杂质E-d5)Trandolapril Impurity 5-d5(Trandolapril EP Impurity E-d5)
Trandolapril Impurity 5-d5(Trandolapril EP Impurity E-d5)
CAS No.1356841-27-4
Chemical FormulaC22H25D5N2O5
Purity>95%询价On request
Trandolapril Impurity 3 (2S,3aR,7aS) structure
3
群多普利杂质3Trandolapril Impurity 3 (2S,3aR,7aS)
Trandolapril Impurity 3 (2S,3aR,7aS)
CAS No.144540-71-6
Chemical FormulaC16H21NO2
Purity>95%现货In stock
10mg25mg50mg100mg
Trandolapril Impurity 7 structure
7
群多普利杂质7Trandolapril Impurity 7
Trandolapril Impurity 7
CAS No.852921-57-4
Chemical FormulaC24H34N2O5
Purity>95%询价On request
10mg25mg50mg100mg
Trandolapril Impurity 8 structure
8
群多普利杂质8Trandolapril Impurity 8
Trandolapril Impurity 8
CAS No.145438-94-4
Chemical FormulaC9H15NO2
Purity>95%询价On request
10mg25mg50mg100mg
Trandolapril Impurity 10 structure
10
群多普利杂质10Trandolapril Impurity 10
Trandolapril Impurity 10
CAS No.107081-15-2
Chemical FormulaC16H21NO2
Purity>95%询价On request
10mg25mg50mg100mg
Trandolapril Impurity 11 structure
11
群多普利杂质11Trandolapril Impurity 11
Trandolapril Impurity 11
CAS No.760916-37-8
Chemical FormulaC16H21NO2
Purity>95%询价On request
10mg25mg50mg100mg
Trandolapril Impurity 12 structure
12
群多普利杂质12Trandolapril Impurity 12
Trandolapril Impurity 12
CAS No.145682-35-5
Chemical FormulaC16H21NO2·HCl
Purity>95%询价On request
10mg25mg50mg100mg
Trandolapril Impurity 13 structure
13
群多普利杂质13Trandolapril Impurity 13
Trandolapril Impurity 13
CAS No.1404480-04-1
Chemical FormulaC22H30N2O5
Purity>95%询价On request
10mg25mg50mg100mg
Trandolapril Impurity 22 structure
22
群多普利杂质22Trandolapril Impurity 22
Trandolapril Impurity 22
CAS No.1260610-97-6
Chemical FormulaC28H38N2O11
Purity>95%询价On request
10mg25mg50mg100mg
Trandolapril Impurity 23 structure
23
群多普利杂质23Trandolapril Impurity 23
Trandolapril Impurity 23
CAS No.1260617-50-2
Chemical FormulaC30H42N2O11
Purity>95%询价On request
10mg25mg50mg100mg
Trandolapril Impurity 24 structure
24
群多普利杂质24Trandolapril Impurity 24
Trandolapril Impurity 24
CAS No.98677-37-3
Chemical FormulaC31H40N2O5
Purity>95%询价On request
10mg25mg50mg100mg
Trandolapril Impurity 25 structure
25
群多普利杂质25Trandolapril Impurity 25
Trandolapril Impurity 25
CAS No.149756-14-9
Chemical FormulaC22H28N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Trandolapril Impurity 26 structure
26
群多普利杂质26Trandolapril Impurity 26
Trandolapril Impurity 26
CAS No.1026380-21-1
Chemical FormulaC30H38N2O5
Purity>95%询价On request
10mg25mg50mg100mg
Trandolapril Impurity 28 structure
28
群多普利杂质28Trandolapril Impurity 28
Trandolapril Impurity 28
CAS No.87269-88-3
Chemical FormulaC30H38N2O5
Purity>95%询价On request
10mg25mg50mg100mg
Trandolapril Impurity 29 structure
29
群多普利杂质29Trandolapril Impurity 29
Trandolapril Impurity 29
CAS No.82717-40-6
Chemical FormulaC9H15NO2
Purity>95%询价On request
10mg25mg50mg100mg
Trandolapril Impurity 31 Hydrochloride structure
31
群多普利杂质31 盐酸盐Trandolapril Impurity 31 Hydrochloride
Trandolapril Impurity 31 Hydrochloride
CAS No.145682-34-4
Chemical FormulaC16H21NO2·HCl
Purity>95%询价On request
10mg25mg50mg100mg
Trandolapril Impurity 31 structure
31
群多普利杂质31Trandolapril Impurity 31
Trandolapril Impurity 31
CAS No.752955-02-5
Chemical FormulaC16H21NO2
Purity>95%询价On request
10mg25mg50mg100mg
Trandolapril Impurity 32 structure
32
群多普利杂质32Trandolapril Impurity 32
Trandolapril Impurity 32
CAS No.83601-86-9
Chemical FormulaC22H30N2O5
Purity>95%询价On request
10mg25mg50mg100mg
Trandolapril Impurity 34 structure
34
群多普利杂质34Trandolapril Impurity 34
Trandolapril Impurity 34
CAS No.960039-95-6
Chemical FormulaC16H21NO2
Purity>95%询价On request
10mg25mg50mg100mg
Trandolapril Impurity 35 structure
35
群多普利杂质35Trandolapril Impurity 35
Trandolapril Impurity 35
CAS No.80828-13-3
Chemical FormulaC9H15NO2
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

群多普利 —— 研究文献与合成路线Trandolapril — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 群多普利 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Trandolapril. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Stability-indicating HPLC determination of trandolapril in bulk drug and pharmaceutical dosage forms
    Al-Hawash LA, Shakya AK, Saleem ML · International journal of analytical chemistry · 2015 · 被引 1cited 1
  2. Simultaneous high-performance thin-layer chromatography densitometric assay of trandolapril and verapamil in the combination preparation
    Kowalczuk D · Journal of AOAC International · 2005 · 被引 3cited 3
  3. High-performance liquid chromatographic assay of trandolapril in capsules
    Gumieniczek A, Hopkała H · Acta poloniae pharmaceutica · 2000 · 被引 3cited 3
  4. Hptlc method development and validation of trandolapril in bulk and pharmaceutical dosage forms
    Sreekanth N, Awen BZ, Rao ChB · Journal of advanced pharmaceutical technology & research · 2010 · 被引 1cited 1

合成与制备工艺专利Synthesis & process patents

  1. PROCESS FOR THE SYNTHESIS OF THE ACE INHIBITOR TRANDOLAPRIL
    KANKAN RAJENDRA NARAYANRAO, RAO DHARMARAJ RAMACHANDRA, PHULL MANJINDER SINGH, SAWANT ASHWINI, et al. · 公开号 KR20080046630KR20080046630 · 2008
  2. PROCESS FOR THE SYNTHESIS OF (2S,3AR,7AS)-OCTAHYDRO-1H-INDOLE CARBOXYLIC ACID AS AN INTERMEDIATE FOR TRANDOLAPRIL
    CHEMBURKAR SANJAY R, REDDY RAJARATHNAM E, REAMER DOUGLAS M, PAVLINA JOHN T, et al. · 公开号 US2011065930US2011065930 · 2011
  3. PROCESSES FOR THE SYNTHESIS OF (2S, 3AR, 7AS)-OCTAHYDRO-1H-INDOLE CARBOXYLIC ACID AS AN INTERMEDIATE FOR TRANDOLAPRIL
    CHEMBURKAR SANJAY R, REDDY RAJARATHMAN E, REAMER DOUGLAS M, PAVLINA JOHN T, et al. · 公开号 WO2011009021WO2011009021 · 2011
  4. Method for preparing trandolapril intermediate
    AILIN ZHU, ZHENHUA XU, WEIMING CHEN, HUAN GU · 公开号 CN101597254CN101597254 · 2009
  5. Processes for the synthesis of (2S, 3aR, 7aS)-octahydro-1H-indole carboxylic acid as an intermediate for trandolapril
    CHEMBURKAR SANJAY R, REDDY RAJARATHMAN E, REAMER DOUGLAS M, PAVLINA JOHN T, et al. · 公开号 AU2010273259AU2010273259 · 2012

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

群多普利 杂质谱研究要点Trandolapril — impurity profiling notes

下面这些是拿到 群多普利 的 24 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 24 impurity entries for Trandolapril, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances